Mavacamten for symptomatic obstructive hypertrophic cardiomyopathy in Chinese adults

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an observational, real-world study enrolling Chinese adults with symptomatic obstructive hypertrophic cardiomyopathy who are starting mavacamten or have recently started it. Participants may be enrolled retrospectively (after starting the drug) or prospectively (before starting), and routine clinical data will be collected during usual care visits. Key data elements include symptoms, echocardiographic measures such as peak LVOT gradient and LVEF, and safety/adverse event reporting. There is no randomization; the aim is to describe effectiveness and safety of mavacamten in routine practice across participating Beijing hospitals.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Participants aged ≥ 18 years (participants enrolled retrospectively: at the time of initial mavacamten prescription), irrespective of gender.
* Participants who have initiated mavacamten (for whom enrolled retrospectively) or are scheduled to initiate mavacamten (for whom enrolled prospectively) based on clinical therapeutic needs.
* Diagnosed with obstructive hypertrophic cardiomyopathy (HCM) consistent with current American College of Cardiology Foundation/American Heart Association, European Society of Cardiology, and Chinese guidelines for diagnosis and treatment of patients with hypertrophic cardiomyopathy, i.e., satisfy criteria below:

  * Has a documented diagnosis of HCM prior to enrollment, and
  * Peak left ventricular outflow tract (LVOT) gradient ≥ 30 mmHg at rest or with provocation in the most recent medical record within 3 months prior to enrollment as assessed by echocardiography.
* Has documented left ventricular ejection fraction (LVEF) ≥ 55%, as measured by resting transthoracic echocardiography (TTE) in the most recent medical record within 3 months prior to enrollment.
* New York Heart Association (NYHA) class II or III symptoms in the most recent medical record within 3 months prior to enrollment.
* For participants enrolled retrospectively, essential baseline information\* and critical data\*\* must be traceable and available. At least one key follow-up time points\*\*\* is required for inclusion.

Note：

\* Essential baseline information, including age, gender, resting or provoked LVOT peak gradient, LVEF, indices of cardiac structure (e.g., maximum LV wall thickness, atrial and ventricular chamber size and volumes), as well as systolic and diastolic function, NYHA functional class.

* Critical data, including resting or provoked LVOT gradient, LVEF, cardiac structure, systolic and diastolic function, dose of mavacamten.

  * Key follow-up time points: including weeks 4, 8, 12, 24, 36, 48, 72 and 96.

    * Voluntary sign informed consent form. Note: For participants enrolled retrospectively, the most recent medical record within 3 months as mentioned in the above requirements refer to the most recent medical record within 3 months prior to the initial mavacamten prescription.

Exclusion Criteria:

* Known HCM phenocopy disease (e.g., Fabry disease, amyloidosis).
* Participants who are expected to undergo major cardiac surgery during the study.
* Prior treatment of obstructive HCM with invasive septal reduction (surgical myectomy or percutaneous alcohol septal ablation \[ASA\] or septal radiofrequency ablation) within 6 months prior to enrollment (participants enrolled retrospectively: within 6 months prior to initial mavacamten prescription); participants with an unsuccessful myectomy or percutaneous ASA or septal radiofrequency ablation performed \>6 months prior to enrollment (participants enrolled retrospectively: within 6 months prior to initial mavacamten prescription) may be enrolled.
* Currently treated with disopyramide or ranolazine (within 14 days prior to enrollment \[participants enrolled retrospectively: within 14 days prior to initial mavacamten prescription\]) or participants who are expected to be taking disopyramide, ranolazine, verapamil in combination with β-receptor blockers, or diltiazem in combination with β-receptor blockers during the study.
* Presence of other diseases that may affect completion of 96 weeks follow-up as assessed by the investigator.
* Participants who are using or are expected to be using moderate to strong CYP2C19 inhibitors/inducers, or strong CYP3A4 inhibitors, moderate to strong CYP3A4 inducers during the study.
* Participants who are participating in other interventional clinical studies.

Where it's running

• Peking Union Medical College Hospital
  Beijing, Beijing Municipality, China Recruiting
• Peking University First Affiliated Hospital
  Beijing, Beijing Municipality, China Recruiting
• The First Affiliated Hospital, Sun Yat-sen University
  Guangzhou, Guangdong, China Recruiting
• The Second Afilliated Hospital of Hebei Medical University
  Jiazhuang, Hebei, China Recruiting
• Suzhou Municipal Hospital
  Suzhou, Jiangsu, China Recruiting
• The Second Hospital of Jilin University
  Changchun, Jilin, China Recruiting

Study contacts

• Study coordinator: BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
• Email: Clinical.Trials@bms.com
• Phone: 855-907-3286

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Long-term safety of HRS-1893 for people with hypertrophic cardiomyopathy

  This study tests the long-term safety of the oral drug HRS-1893 in people with hypertrophic cardiomyopathy who previously received HRS-1893.

  Recruiting Phase 2 Shandong Suncadia Medicine Co., Ltd. · Beijing, Beijing Municipality · NCT07021963

• Study of heart conditions using advanced imaging techniques

  This study is trying to find out what causes different heart conditions in Hispanic and African American people in the Bronx by using advanced imaging techniques.

  Recruiting Montefiore Medical Center · The Bronx, New York · NCT06610019

• Registry for Rare Diseases

  This study is creating a detailed registry to collect information on rare diseases like amyloidosis and sarcoidosis to help improve how they are diagnosed and treated.

  Recruiting Hospital Italiano de Buenos Aires · Buenos Aires, Buenos Aires · NCT06573723

• Comparing inspiratory muscle training and Baduanjin exercises for heart health

  This study tests whether breathing exercises or a special exercise program can help people with hypertrophic cardiomyopathy improve their lung function, exercise ability, and overall quality of life.

  Recruiting Istanbul University - Cerrahpasa · Istanbul · NCT06490250

• Using advanced imaging to evaluate heart muscle scarring in various heart conditions

  This study is testing a new imaging method to see how heart scarring changes over time in people with certain heart conditions.

  Recruiting University of Edinburgh · Edinburgh, Scotland · NCT06409585

• Registry for Hypertrophic Cardiomyopathy in Taiwan

  This study is trying to gather information about hypertrophic cardiomyopathy and related diseases in adults in Taiwan to improve how they are diagnosed and treated.

  Recruiting Far Eastern Memorial Hospital · New Taipei City · NCT06381778

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.